Table 2 Clinical response rate to neoadjuvant treatment

From: Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate

 

No. of patients (%)

 

Clinical response

Mammographic response

Echographic response

Global clinical response

Overall (n=80)

 Complete response (CR)

27 (36.0)

18 (45.0)

11 (17.5)

15 (19.0)

 Partial response (PR)

28 (37.3)

10 (25.0)

31 (49.2)

39 (49.4)

 Minor response/no change

11 (14.7)

5 (12.5)

11 (17.5)

17 (21.5)

 Progression

9 (12.0)

7 (17.5)

10 (15.8)

8 (10.1)

 ORR (CR+PR) No. (%; 95 CI)

55 (73.3; 63.3–83.3)

28 (70.0; 55.8–84.2)

42 (66.7; 55.1–78.3)

54 (68.4; 58.1–78.7)

Group 1 (n=45)

 ORR (CR+PR) No. (%; 95 CI)

34 (77.2; 64.8–89.6)

18 (66.7; 48.9–84.5)

27 (75.0; 60.9–89.1)

34 (75.6; 63.1–88.1)

Group 2 (n=35)

 ORR (CR+PR) No. (%; 95 CI)

21 (67.8; 51.4–84.2)

10 (77.0; 45.0–94.7)

15 (55.5; 36.8–74.2)

20 (58.9; 42.4–75.4)

  1. ORR: overall response rate.
Back to article page